As consultation on the 'new' Cancer Drugs Fund closes this week, Leela Barham reviews the impact of England's guidance on end-of-life treatments and the implications of these broader changes.
Leela Barham considers the history of Scottish Medicines Consortium (SMC) drug approvals in Scotland and whether the trend is towards greater access in recent years.
